Literature DB >> 26903704

Report of a case of papillary thyroid carcinoma in association with Hashimoto's thyroiditis.

Chukwudi Onyeaghana Okani1, Benjamin Otene2, Terhemba Nyaga2, Joseph Ngbea2, Agaba Eke3, Felix Edegbe4, Daniel Anyiam5.   

Abstract

Hashimoto thyroiditis (HT) is an autoimmune disease, known to be the most common cause of hypothyroidism in nonendemic goitrous areas. It is usually characterized by symmetric, painless, and diffused but sometimes localized swelling of the thyroid gland with features of hypothyroidism. Papillary thyroid carcinoma (PTC), on the other hand, is the most common yet less aggressive form of thyroid cancer, especially in iodine-deficient areas. The coexistence of the two diseases is possible but not common. This case study reports a 50-year-old female with a 10-year history of a huge goiter, which was essentially symptom-free until about 3 months prior to presentation when the patient started complaining of neck pain, dysphagia, productive cough, and cold intolerance. Physical examination revealed focal cystic and tender area in the multinodular swelling and associated cervical lymphadenopathy on the left side of the neck. The serum thyroid stimulating hormone was high, sub-normal T3, and the T4 was low. The fine needle aspiration cytology yielded 10 ml of aspirate of pus admixed with altered blood which on microscopy showed a few suspicious follicular epithelial cells with open nuclei admixed with mainly neutrophil polymorphs, siderophages, and foam cells in a hemorrhagic background. The patient had an incision biopsy that showed areas displaying PTC and HT.

Entities:  

Keywords:  Hashimoto thyroiditis; Hurthle cell; histopathology; papillary thyroid carcinoma

Year:  2015        PMID: 26903704      PMCID: PMC4743296          DOI: 10.4103/0300-1652.171612

Source DB:  PubMed          Journal:  Niger Med J        ISSN: 0300-1652


INTRODUCTION

The name Hashimoto thyroiditis (HT) was derived from the 1912 report by Hashimoto describing patients with goiter and intense lymphocytic infiltration of the thyroid (struma lymphomatosa).1 HT is known to be the most common cause of hypothyroidism in iodine-deficient areas of the world.2 Papillary carcinomas are also the most common form of thyroid cancer, and majority of them are associated with previous exposure to ionizing radiation. The association of papillary thyroid carcinoma (PTC) and HT has been a subject of debate, since it was first described by Dailey et al. in 1955.345 Lee et al., Cipolla et al., Liu et al., Pino Rivero et al., and Singh et al. in their various studies concluded that there was an association between HT and PTC.6789 We found on a microscopic examination of a thyroid biopsy from 50-year-old female, foci showing HT, PTC, and Hurthle cell hyperplasia; and it is hereby being reported.

PATIENTS AND OBSERVATION

The patient was a 50-year-old woman who initially presented to the Surgery Department of Benue State University Makurdi with a 10-year history of goiter. The swelling increased gradually in size and appeared multinodular in contour, approximating 10 cm × 8 cm [Figure 1] and was all the while painless until about 3 months prior to presentation to the Surgical Outpatient Unit of the Hospital with pain and tenderness, and mild difficulty in swallowing. The pain was described as dull which gradually increased in intensity necessitation her decision to seek medical intervention. She also complained of intolerance to cold and easy fatigability. The serum thyroid-stimulating hormone (TSH) was high −40.5 µIU (normal reference range of 0.4–6.2 µIU), and the T4 was low- < 50 nmol/L while T3 was subnormal. The full blood count revealed mild microcytic hypochromic anemia with normal differential counts. Urea and creatinine were within the normal reference range. The erythrocyte sedimentation rate was mildly elevated–35 mm/h (Westergren method). The fine needle aspiration cytology done yielded about 10 ml of aspirate of pus admixed with altered blood, and the microscopic examination of the smears showed a few suspicious follicular epithelial cells with open nuclei, and pseudocytoplasmic nuclear inclusions in a background containing mainly neutrophil polymorphs, lymphocytes, foam cells, and hemosiderin-laden macrophages. The patient had an incision biopsy which on microscopic examination showed areas with PTC, HT, and Hurthle cell metaplastic changes [Figures 2–4].
Figure 1

Multinodular goiter in a 50-year-old woman diagnosed with concurrent Hashimoto thyroiditis, papillary thyroid carcinoma, and Hurthle cell adenoma. (a) Anterior view of goiter with focal cystic areas filled with pus. (b) The lateral view of the goiter showing extension of the swelling into the posterior aspect of the neck

Figure 2

Hashimoto thyroiditis. Residual thyroid follicle being destroyed by a dense lymphocytic infiltrates

Figure 4

Papillary carcinoma of the thyroid. The microscopic appearance of a papillary carcinoma showing cells with characteristic empty-appearing nuclei called “Orphan Annie eye” nuclei

Multinodular goiter in a 50-year-old woman diagnosed with concurrent Hashimoto thyroiditis, papillary thyroid carcinoma, and Hurthle cell adenoma. (a) Anterior view of goiter with focal cystic areas filled with pus. (b) The lateral view of the goiter showing extension of the swelling into the posterior aspect of the neck Hashimoto thyroiditis. Residual thyroid follicle being destroyed by a dense lymphocytic infiltrates The microscopic appearance of a papillary carcinoma showing well-formed papillae and cells with ground glass nuclei Papillary carcinoma of the thyroid. The microscopic appearance of a papillary carcinoma showing cells with characteristic empty-appearing nuclei called “Orphan Annie eye” nuclei

DISCUSSION

In a research by Repplinger et al. that sought to answer a question, “Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer?” They discovered that a subgroup of patients with HT had strong associations with PTC.2 They also documented that there was a significantly greater percentage of PTC occurrence in females with HT as compared with females without HT.2 Gasbarri et al. in a study showed that the diagnosis of HT was a representation of a variety of disease mechanisms which influenced the clinical presentation of the disease including PTC.10 It is possible to extrapolate that certain factors influence varying thyroid growth including goiters or carcinomas. This index case certainly substantiates the causative relationship between HT and PTC. Some authors have proposed mechanisms and associations between the two lesions. Expression of the RET/PTC1 and RET/PTC3 oncogenes in HT patients was documented by Wirtschafter et al.11 as a major association, and this hypothesis was supported by Arif et al. who demonstrated that both diseases have a similar immunophenotypic expression, histological features, and the RET/PTC gene rearrangement on molecular studies.12 Moreover, Unger et al. documented p63 expression in a patient with HT, who also had concurrent papillary thyroid cancer.13 This hypothesis was further substantiated by Burstein et al. in their work where they made some propositions that the initiator of the two diseases was pluripotent p63-positive stem cell remnants.14 The intimate relationship between HT and PTC in this report goes further to substantiate the proposals made by these researchers that the two diseases may most probably have similar or common triggering factors. Another angle to this discuss is whether serum thyroid TSH has a causal role in the subsequent development of PTC in preexisting HT. Boelaert et al. documented that serum TSH is an independent predictor of malignancy in thyroid nodules,15 and Haymart et al. further showed that higher serum TSH in thyroid correlated with extrathyroidal extension of disease.16 Jonklaas et al. in their work concluded that higher TSH concentrations, even within the normal range, are associated with a subsequent diagnosis of thyroid cancer in individuals with thyroid abnormalities.17 The hypothesis that TSH stimulates the growth or development of thyroid malignancy during its early or preclinical phase was further supported by their work. Jonklaas et al. also demonstrated that patients with thyroid cancer also have lower T3 levels than patients with benign disease.17 This finding is in keeping with the clinical profile of this index case. It is interesting to conclude by joining Boelaert with the consensus opinion that serum TSH concentration can be used as a diagnostic adjunct in the identification of high-risk patients, who may require further investigation and/or surgical interventions.18

CONCLUSION

A high index of suspicion is required for establishing the coexistence of Hashimoto's thyroiditis with PTC; therefore, clinicians must thoroughly evaluate patients with Hashimoto's thyroiditis while pathologists have to always do a thorough job by painstakingly doing a macroscopic and microscopic examination of thyroid specimens more especially, ones with suspected or confirmed Hashimoto's thyroiditis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  17 in total

1.  Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland.

Authors:  M E DAILEY; S LINDSAY; R SKAHEN
Journal:  AMA Arch Surg       Date:  1955-02

2.  Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome.

Authors:  B Singh; A R Shaha; H Trivedi; J F Carew; A Poluri; J P Shah
Journal:  Surgery       Date:  1999-12       Impact factor: 3.982

3.  Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration.

Authors:  K Boelaert; J Horacek; R L Holder; J C Watkinson; M C Sheppard; J A Franklyn
Journal:  J Clin Endocrinol Metab       Date:  2006-07-25       Impact factor: 5.958

4.  Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer?

Authors:  Daniel Repplinger; Anna Bargren; Yi-Wei Zhang; Joel T Adler; Megan Haymart; Herbert Chen
Journal:  J Surg Res       Date:  2007-10-29       Impact factor: 2.192

5.  The association between serum TSH concentration and thyroid cancer.

Authors:  Kristien Boelaert
Journal:  Endocr Relat Cancer       Date:  2009-07-20       Impact factor: 5.678

6.  Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer.

Authors:  Jacqueline Jonklaas; Hala Nsouli-Maktabi; Steven J Soldin
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

7.  Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link?

Authors:  Pamela Unger; Michelle Ewart; Beverly Y Wang; Li Gan; D Stave Kohtz; David E Burstein
Journal:  Hum Pathol       Date:  2003-08       Impact factor: 3.466

8.  Hashimoto thyroiditis coexistent with papillary thyroid carcinoma.

Authors:  Calogero Cipolla; Luigi Sandonato; Giuseppa Graceffa; Salvatore Fricano; Adriana Torcivia; Salvatore Vieni; Stefania Latteri; Mario Adelfio Latteri
Journal:  Am Surg       Date:  2005-10       Impact factor: 0.688

9.  Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension.

Authors:  Megan R Haymart; Simone L Glinberg; Jing Liu; Rebecca S Sippel; Juan C Jaume; Herbert Chen
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478

10.  Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis.

Authors:  A Gasbarri; S Sciacchitano; A Marasco; M Papotti; A Di Napoli; A Marzullo; P Yushkov; L Ruco; A Bartolazzi
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more
  2 in total

1.  Application of Preoperative Ultrasonography in the Diagnosis of Cervical Lymph Node Metastasis in Thyroid Papillary Carcinoma.

Authors:  Ailong Zhang; Shenglan Wu; Zhenhui You; Wenkai Liu
Journal:  Front Surg       Date:  2022-02-28

2.  Concurrence of Papillary Thyroid Carcinoma and Hürthle Cell Carcinoma in an Iranian Woman with Hashimoto's Thyroiditis.

Authors:  Fatemeh Samiee-Rad; Sohayla Farajee; Erfan Torabi
Journal:  Iran J Pathol       Date:  2019-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.